Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help carboplatin and paclitaxel albumin-stabilized nanoparticle formulation work better by making tumor cells more sensitive to the drugs. Giving chemotherapy with or without vorinostat before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This randomized phase II trial is studying how well giving carboplatin together with paclitaxel albumin-stabilized nanoparticle formulation works with or without vorinostat in treating women with breast cancer that can be removed by surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborator: National Cancer Institute (NCI)
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Vorinostat

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed infiltrating ductal breast cancer by core needle biopsy

• Mixed ductal and lobular disease allowed

• Infiltrating lobular cancer allowed in the run-in portion only

• Unresected, clinically measurable disease, meeting 1 of the following clinical staging criteria:

• T2, T3, or T4 lesion, any N, M0

• T1c, N1-3,M0

• Patients with skin metastases to the ipsilateral breast for whom chemotherapy is planned prior to definitive surgery are eligible for the primary study portion

• HER2-negative disease

• Hormone receptor status* meeting 1 of the following criteria:

• Estrogen receptor (ER)-negative and progesterone receptor (PR)-negative

• ER-positive (grade II or III) and PR-positive or PR-negative NOTE: *Any ER or PR status for the run-in portion

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1

• Menopausal status not specified

• ANC ≥ 1,500/mm³

• Platelet count ≥ 150,000/mm³

• Hemoglobin ≥ 9 g/dL

• Creatinine ≤ 1.5 times the upper limit of normal (ULN)

• Creatinine clearance ≥ 50 mL/min

• Total bilirubin normal

• AST(SGOT) and ALT(SGPT) ≤ 2.5 times (ULN)

• alkaline phosphatase ≤ 2.5 times ULN

• PT such that INR ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and PTT ≤ ULN

• Adequate cardiac function defined as no evidence of PR prolongation or AV block on baseline electrocardiogram (ECG)

• Willing to use effective, non-hormonal contraception while on treatment and for at least 3 months thereafter

• Not pregnant or nursing

• No pre-existing peripheral neuropathy ≥ grade 2

• No history of severe hypersensitivity reaction to any drug formulated with polysorbate 80 or to E. coli-derived products

• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat

• No medical condition which, in the opinion of the investigator, puts the patient at risk of potentially serious complications while on this therapy

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since prior valproic acid or other histone deacetylase inhibitor

• No prior chemotherapy, radiotherapy, or endocrine therapy for this cancer

• Prior tamoxifen or raloxifene or another agent for prevention of breast cancer allowed as long as the patient has discontinued the treatment ≥ 1 month prior to baseline study biopsy

• No systemic treatment for prior cancer within the past 5 years (primary study portion)

• No prior or ongoing systemic treatment for this cancer (primary study portion)

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No other concurrent histone deacetylase inhibitor

• No other concurrent chemotherapy, antiestrogen therapy, radiotherapy, or other investigational systemic therapy

• No other concurrent biologic therapy

• No other concurrent investigational drugs